Aug 19, 2026
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
Read more
Aug 04, 2026
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Read more
Jul 28, 2026
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
Read more
Jul 08, 2026
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
Read more
Jun 03, 2026
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
Read more
Displaying 1 - 10 of 27